Teva’s generics offering – which includes a community pharmacy partnership scheme, services and customer service – was singled out at an awards ceremony which recognises and rewards the hard work done by pharmacists. It also rewards the manufacturers and products that have stood out throughout the year – either through exceptional service, or through customer demand.
Bruno Barcelos, Senior Director Generics and Teva UK, said: “Winning this award for an unmatched 14th consecutive time is a huge honour for us. What makes this particularly special is the fact that it is voted for by our customers – the readers of Pharmacy Business Magazine. The team and I are really proud of this and are constantly working to make sure that our offering is tailored to our customers’ and their patients’ needs.”
# ENDS #
For media enquiries, contact the Teva UK Limited Communications team on 01977 628500, or email email@example.com
Notes to Editors:
About Teva UK Limited
Teva UK Limited is one of the UK’s top ten pharmaceutical manufacturers, with a presence in the generics, over-the-counter, branded respiratory, central nervous system and hospitals markets. It has the widest range of any UK generic pharmaceutical company and markets solid and liquid dose, injectable and respiratory medicines to healthcare professionals. The company is part of Teva Pharmaceutical Industries Ltd. For more information, visit www.tevauk.com.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to millions of patients every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva's net revenues in 2015 amounted to $19.7 billion. For more information, visit www.tevapharm.com.